What question did this study set out to answer?

This research aims to evaluate how PEGylated liposomes affect the pharmacokinetics and efficacy of kaempferol in cancer treatment.

May 10, 2026Open Access

PEGylated liposomes enhance the pharmacokinetics, biodistribution, anticancer efficacy, and safety of Kaempferol, a phytomolecule enrolled in clinical trials

Puntos clave

This research aims to evaluate how PEGylated liposomes affect the pharmacokinetics and efficacy of kaempferol in cancer treatment.
Utilized MTT assay to assess cytotoxicity with a concentration of 153.57 μM.
Conducted acute and sub-acute toxicity assessments to evaluate safety.
Assessed tumor reduction in an orthotopic syngeneic N1S1 rat model.
Significant tumor reduction was observed in PEG-LP-KP treated groups compared to vehicle control (exact metrics not provided).
PEG-LP-KP exhibited a favorable safety profile with no severe toxic effects identified.

Resumen

of 153.57 μM as assessed by the MTT assay. PEG-LP-KP demonstrated a favorable safety profile, as evidenced by both acute and sub-acute toxicity assessments. We also found a significant tumor reduction in PEG-LP-KP treated animal groups compared to vehicle control as assessed by Orthotopic syngeneic N1S1 rat model.

Me gusta

Guardar

Ver artículo completo